-2.02%
Today
Loading 1D prices…
Company profile
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Sector
Health Care
Industry
Surgical & Medical Instruments & Apparatus
Exchange
Nasdaq
Display currency
USD
Location
Acton, MA, United States
Employees
5.4K
Fiscal year end
1231
CIK
1145197
Session & valuation
Latest annual period
Deterministic peer set
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| GKOSGlaukos Corporation Common Stock | $9.9B | $507.4M | -36.99% | -$3.28 | -1.84% | Buy |
| GMEDGlobus Medical Inc. Class A Common Stock | $10B | $2.9B | +18.30% | $3.92 | +0.87% | Buy |
| BAXBaxter International Inc. Common Stock | $12.3B | $11.2B | -8.51% | -$1.87 | -1.59% | Hold |
| PENPenumbra Inc. Common Stock | $12.5B | $1.4B | +12.66% | $4.52 | +0.00% | Hold |
| MMEDMiniMed Group Inc. Common Stock | $6.3B | $3.1B | -10.74% | -$1.30 | +0.13% | Buy |